Evidence map›Paper›PMID 28409821›Full record

ArticleBritish journal of pharmacology2017

Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.

Raghu Ganugula, Meenakshi Arora, Patcharawalai Jaisamut, Ruedeekorn Wiwattanapatapee, Heather G Jørgensen, Vinod P Venkatpurwar, Beiyan Zhou, Aline Rodrigues Hoffmann, Rita Basu, Shaodong Guo and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Raghu GanugulaDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX, USA.
Meenakshi AroraDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX, USA.
Patcharawalai JaisamutDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX, USA.
Ruedeekorn WiwattanapatapeeDepartment of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla, Thailand.
Heather G JørgensenPaul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Vinod P VenkatpurwarStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Beiyan ZhouDepartment of Immunology, University of Connecticut Health Center, Farmington, CT, USA.
Aline Rodrigues HoffmannDepartment of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA.
Rita BasuThe Integrated Carbohydrate Physiology and Translation Laboratory, Mayo Clinic, Rochester, MN, USA.
Shaodong GuoDepartment of Nutrition and Food Science, Texas A&M University, College Station, TX, USA.
Naga Venkata Ravi Kumar MajetiDepartment of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX, USA.ORCID 0000-0001-5606-401X
Texas A&M University · USPrince of Songkla University · THBlood Cancer UK · GBMayo Clinic · USUConn Health · USUniversity of Strathclyde · GB

Funding

MicroRNA Regulated Macrophage Polarization in Adipose Tissue InflammationR01DK098662 · NIDDK · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ZHOU, BEIYAN · 2013 to 2017
$1.6M
NIDDK NIH HHS R01 DK098662
6 · The paper itself

Abstract

background and purposeApproaches to prevent selective and progressive loss of insulin-producing beta cells in Type 1 diabetes mellitus (T1DM) will help to manage this prevalent and devastating disease. Curcumin (CUR), a natural anti-inflammatory substance, suppresses diabetes-associated inflammation and cell death. However, very high doses need to be used because of poor oral bioavailability, making it difficult to translate the anti-inflammatory actions to clinical situations. EXPERIMENTAL APPROACH: We have prepared biodegradable nanosystems encapsulating curcumin (nCUR), resulting in at least nine-fold improvement in oral bioavailability. Here, we tested the ability of nCUR to prevent streptozotocin (STZ)-induced inflammation and apoptosis in pancreatic islets and beta cells, in rats. KEY

resultsNon-fasted rats pretreated with 10 or 50 mg·kg CONCLUSIONS AND IMPLICATIONS: Together, these data indicate a potentially translatable dose of nCUR that is safe and efficacious in improving beta cell function, which could prevent T1DM.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalApoptosisCurcuminDiabetes Mellitus, Type 1Dose-Response Relationship, DrugInflammationInsulin-Secreting CellsMaleNanostructuresRatsRats, Sprague-DawleyStreptozocinStructure-Activity RelationshipAnti-Inflammatory Agents, Non-SteroidalCurcuminStreptozocin

Identifiers

PMID28409821
PMCPMC5466524
OpenAlexW2606328821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.